Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 5, 2015, Pages 1723-1730

  Hassan, Memy Hegazy ^a,b   Abd Allah, Gamil Mohamed ^b  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Diabetes mellitus type 2; Gliclazide; Glimepiride; Metformine; Serum homocysteine

Indexed keywords

CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; GLICLAZIDE; GLICLAZIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; VOMITING; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FOLIC ACID; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84940647620     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Aghamohammadi V, Gargari BP and Aliasgharzadeh A (2011). Effect of folic acid supplementation on homocysteine, serum total antioxidant capacity, and malondialdehyde in patients with type 2 diabetes mellitus. J. Am. Coll. Nutr., 30(3):210-215.
2. Alberti KG and Zimmet PZ (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med., 15:539-553.
3. American diabetes association (2008). Standards of medical care in diabetes-2008. Diabetes Care, 31:S12-S54.
4. Arvind K, Pradeepa R, Deepa R and Mohan V (2002). Diabetes & coronary artery disease. Ind. J. Med. Res., 116:163-176.
5. Bell DSM (2006). Do sulfonylurea drugs increase the risk of cardiac events? CMAJ, 174:185-186.
6. Cefalu WT (2005). Glycemic control and cardiovascular disease should we reassess clinical goals? N. Engl. J. Med., 353:2707-2708.
7. Dailey GE (2003). Glyburide/metformin tablets: A new therapeutic option for the management of type 2 diabetes. Expert. Opin. Pharmacother., 4:1417-1430.
8. De Fronzo RA (1999). Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med., 131:281-303.
9. Eikelboom JW, Lonn E, Genest J, Jr, Hankey G, and Yusuf S (1999). Homocyst (e) ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann. Intern. Med., 131:363-375.
10. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y and Nishizawa Y (2001). Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care, 24:533-538.
11. Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P and Merante DA (1999). Comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta. Diabetol., 36:61-65.
12. Fonseca VA, Fink LM and Kern PA (2003). Insulin sensitivity and plasma homocysteine concentrations in non-diabetic obese and normal weight subjects. Atherosclerosis, 167(1):105-109.
13. Fonseca V, Guba SC and Fink LM (1999). Hyperhomocysteinemia and the endocrine system: Implications for atherosclerosis and thrombosis. Endocrine Reviews, 20:738-759.
14. Frantzen F, Faaren AL, Alfheim I and Nordhei AK (1998). Enyzme conversion immunoassay for determining total homocysteine in plasma or serum. Clin. Chem., 44:311-316
15. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA and Rodgers GM (1993). Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb., 13:1327-1233.
16. Haffner SM, Lehto S, Ronnemaa T, PyöräläK and Laakso M (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 339:229-234.
17. Hamadi N, Mansour A, Hassan MH, Khalifi-Touhami F and Badary O (2012). Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol., 26(10):384-392.
18. Hermann LS, Schersten B and Melander A (1994). Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet. Med., 11:953-960.
19. Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 359:1577-1589
20. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, and Stehouwer CD (2000). Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation, 101:1506-1511.
21. Jacobsen DW (1996). Determinants of hyperhomocysteinemia: A matter of nature and nurture. Am. J. Clin. Nutr., 64:641-642.
22. King GL and Loeken MR (2004). Hyperglycemiainduced oxidative stress in diabetic complications. Histochem. Cell Biol., 122:333-338.
23. Kiritoshi S, Nishikawa T, Sonoda K, Kukidome D, Senokuchi T, Matsuo T, Matsumura T, Tokunaga H, Brownlee M and Araki E (2003). Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: Potential role in diabetic nephropathy. Diabetes, 52:2570-2577.
24. Krentz AJ and Bailey CJ (2005). Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs, 65:385-411.
25. Majors A, Ehrhart LA and Pezacka EH (1997). Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by sm oothmuscle cells. Arterioscler. Thromb. Vasc. Biol., 17(10):2074-2081.
26. Monnier L, Colette C, Dunseath GJ and Owens DR (2007). The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care, 30:263-269.
27. Müller G, Satoh Y and Geisen K (1995). Extra pancreatic effects of sulfonylureas A comparison between glimepiride and conventional sulfonylureas. Diabetes Res. Clin. Pract., 28(Suppl):S115-S137.
28. Munshi MN, Stone A, Fink L and Fonseca V (1996). Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macro vascular disease. Metabol., 45:133-135.
29. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B (2009). American diabetes association; European association for the study of diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American diabetes association and the European association for the study of diabetes. Diabetologia, 52:17-30.
30. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH and Lindenbaum J (1995). Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet, 346:85-89.
31. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I and Brownlee M (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404:787-790.
32. Nishinaga M, Ozawa T and Shimada K (1993). Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J. Clin. Invest, 92:1381-1386.
33. Palareti G, Salardi S, Piazzi S, Legnani C, Poggi M, Grauso F, Caniato A, Coccheri S and Cacciari E (1986). Blood coagulation changes in homocystinuria: Effects of pyridoxine and other specific therapy. J. Pediatr., 109:1001-1006.
34. Park KS, Kim JH, Kim MS, Kim JM, Kim SK, Choi JY, Chung MH, Han B, Kim SY and Lee HK (2001). Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes, 50:2837-2841.
35. Raz I (2013). Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care, 36:S139-144.
36. Rendell M (2004). The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 64:1339-1358.
37. Rodgers GM and Kane WH (1986). Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J. Clin. Invest, 77:1909-1916.
38. Sahin M, Tutuncu NB, Ertugrul D, Tanaci N and Guvener ND (2007). Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate and vitamin B12 in patients with type 2 diabetes mellitus. J. Diabetes Complications, 21(2):118-123.
39. Sahreen S, Khan MR and Khan RA (2011). Hepatoprotective effects of methanol extract of Carissa opaca leaves on CCl4-induced damage in rat. BMC Complement. Altern. Med., 11:48.
40. Shipchandler MT and Moore EG (1995). Rapid, fully automated measurement of plasma homocyst (e) ine with the Abbott Imx Analyser. Clin. Chem., 41:991-994
41. Stehouwer CD, Gall MA, Hougaard P, Jakobs C and Parving HH (1999). Plasma homocysteine concentration predicts mortality in noninsulindependent diabetic patients with and without albuminuria. Kidney Int., 55:308-314.
42. Taskinen MR (2002). Diabetic dyslipidemia. Atherosclerosis. Suppl., 3:47-51.
43. Thambyrajah J and Townend JN (2000). Homocysteine and atherothrombosis mechanisms for Injury. Eur. Heart J., 21:967-974.
44. Tomkin G, Hadden D, Weaver J and Montgomery D (1971). Vitamin-B12 status of patients on long-term metformin therapy. Br. Med. J., 2:685-687.
45. UK. Prospective diabetes study group (1998). UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care, 21:87-92.
46. Waugh J, Keating GM, Plosker GL, Easthope S and Robinson DM (2006). Spotlight on pioglitazone in type 2 diabetes mellitus. Treat Endocrinol., 5(3):189-191.
47. Wojtczak L and Schonfeld P (1993). Effect of fatty acids on energy coupling processes in mitochondria. Biochim. Biophys. Acta., 1183:41-57.
48. Wolff SP, Jiang ZY and Hunt JV (1991). Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad. Biol. Med., 10:339-352.
49. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger Van Der Burg B, Donker AJ and Stehouwer CD (2003). Effects of short term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: A randomized, control-controlled trial. J. Int. Med., 254(5):455-463.
50. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, Xu Y, Zhang L and Li DD (2008). Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARS expression in diabetic hyperlipidemic rats. Biol. Pharm. Bull., 31(6):1169-1176.